The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-28), Zevra Therapeutics's share price is
$4.52.
Zevra Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.29. Therefore, Zevra Therapeutics's PE Ratio (TTM) for today is At Loss.
The historical rank and industry rank for Zevra Therapeutics's PE Ratio (TTM) or its related term are showing as below:
ZVRA'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss Med: At Loss Max: At Loss
Current: At Loss
ZVRA's PE Ratio (TTM) is ranked worse than 100% of 249
companies
in the Biotechnology industry
Industry Median: 26.65
vs ZVRA: At Loss
During the past 3 years, the average EPS without NRIGrowth Rate was 23.70% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 55.40% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 33.00% per year.
During the past 11 years, Zevra Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 68.40% per year. The lowest was -51.40% per year. And the median was 27.75% per year.
Zevra Therapeutics's EPS (Basic) for the
three
months ended in Dec. 2023 was $-0.40.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.29.
Zevra Therapeutics PE Ratio (TTM) Historical Data
The historical data trend for Zevra Therapeutics's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Zevra Therapeutics's PE Ratio (TTM)
For the Biotechnology subindustry, Zevra Therapeutics's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zevra Therapeutics's PE Ratio (TTM) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Zevra Therapeutics's PE Ratio (TTM) falls into.
Zevra Therapeutics PE Ratio (TTM) Calculation
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Zevra Therapeutics's Share Price of today is $4.52.
Zevra Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.29.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Zevra Therapeutics (NAS:ZVRA) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Zevra Therapeutics PE Ratio (TTM) Related Terms
Thank you for viewing the detailed overview of Zevra Therapeutics's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.
Zevra Therapeutics (Zevra Therapeutics) Business Description
Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZVRA has been successfully added to your 